1)Fisher B, Redmond C, Fisher ER, et al:Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985
2)Sonoo H, Noguchi S, On behalf of the academic committee of the Japanese Breast Cancer Society:Results of questionnaire survey on breast cancer surgery in Japan 2004-2006. Breast Cancer 15:3-4, 2008
3)Veronesi U, Paganelli G, Viale G, et al:A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546-553, 2003
4)Whelan T, MacKenzie R, Julian J, et al:Randomized trial of breast Irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94:1143-1150, 2002
5)Watanabe T, Sano M, Takashima S, et al:Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, Fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer:National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 27:1368-1374, 2009
6)Park Y, Okamura K, Mitsuyama S, et al:Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage Ⅰ, Ⅱ, or ⅢA lymph node-positive breast cancer:a comparative study. Br J Cancer 101:598-604, 2009
/Doxil)versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449, 2004
8)Gradishar WJ, Tjulandin S, Davidson N, et al:Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803, 2005
9)Jakesz R, Hausmaninger H, Kubista E, et al:Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer―Austrian Breast and Colorectal Cancer Study Group Trial5. J Clin Oncol 20:4621-4627, 2002
10)Arimidex, Tamoxifen, Alone or in Combination(ATAC)Trialists' Group, Forbes JF, Cuzick J, et al:Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
11)Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al:Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
12)Romond EH, Perez EA, Bryant J, et al:Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
13)Slamon D, Eiermann W, Robert N, et al:BCIRG 006:2nd interim analysis phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(AC-T)with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(AC-TH)with docetaxel, carboplatin and trastuzumab(TCH)in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium, 2006
14)Geyer CE, Forster J, Lindquist D, et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
15)Lin NU, Carey LA, Liu MC, et al:Phase Ⅱ trial of lapatinib for brain metastases in patients with HER2+breast cancer. J Clin Oncol 24(suppl 18s):abstr 503, 2006
16)Baselga J, Imadalou K, Paton V, et al:Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab+trastuzumab in HER2+metastatic breast cancer patients previously treated with trastuzumab. Cancer Res 69(249s):abstr 3138, 2009
17)Burstein HJ, Sun Y, Tan AR, et al:Neratinib(HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor:Phase Ⅱ result in patients with advanced HER-2+breast cancer. Cancer Res 69(73s):abstr 37, 2009
18)Miller K, Wang M, Gralow J, et al:Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
19)Rugo HS, Stopeck A, Joy AA, et al:A randomized, double-blind phase Ⅱ study of the oral tyrosine kinase inhibitor(TKI)axitinib(AG-013736)in combination with docetaxel(DOC)compared to DOC plus placebo(PL)in metastatic breast cancer(MBC). J Clin Oncol 25(suppl 18):abstr 1003, 2007
20)Burstein HJ, Elias AD, Rugo HS, et al:Phase Ⅱ study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
21)Slamon D, Gomez HL, Kabbinavar FF, et al:Randomized study of pazopanib+lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 26(suppl 15):abstr 1016, 2008